Effects of chronic treatment with losartan and enalaprilat on [3H]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats

American Journal of Hypertension

Volumn 9, Issue 1, 1996, Pages 61-69

  Foucart, Sylvain ^a   Patrick, Susan K ^a,b   Oster, Laurence ^a   De Champlain, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin converting enzyme inhibitor; Losartan; Norepinephrine release; Presynaptic modulation; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; FENOTEROL; IDAZOXAN; LOSARTAN; NOREPHEDRINE; OXYMETAZOLINE;

ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; DRUG RELEASE; HEART ATRIUM; HUMAN; HYPERTENSION; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030026440     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00297-9     Document Type: Article

References (45)

1. Reid IA: Endocrine regulation of body fluid balance, in Staub NC, Taylor AE (eds): Edema. New York, Raven Press, 1984, pp 353-369.
2. Reid IA: Interactions between Ang II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992;262:E763-E778.
3. Sealey JE, Laragh JH: The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. New York, Raven Press, 1990, pp 1287-1317.
4. Brunner HR, Nussberger J, Waeber B: Blockade of the renin-angiotensin system in man: converting enzyme inhibitors, renin inhibitors and angiotensin II antagonists. Curr Opin Cardiol 1991;6:724-730.
5. DeCarvalho JGR, Dunn FG, Kem DC, et al: Hemodynamic correlates of saralasin-induced arterial pressure changes. Circulation 1978;57:373-378.
6. Cushman DW, Ondetti MA, Cheung HS, et al: Inhibitors of angiotensin converting enzyme, in Johnson JA, Anderson RA (eds): The Renin Angiotensin System. New York, Plenum Publishing Corp., 1980, pp 199-225.
7. Brunner HR, Nussberger J, Waeber B: The present molecules of converting enzyme inhibitors. J Cardiovasc Pharmacol 1985;7(suppl 1):2-11.
8. Benetos A, Gavras I, Gavras H: Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension 1986;8:1089-1092.
9. Wiemer G, Schölkens BA, Becker RHA, Busse R: Ramipril enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-563.
10. Unger T, Kaufman-Buhler I, Scholkens B, Ganten D: Brain converting enzyme inhibition: a possible mechanism for the antihypertensive action of captopril in spontaneously hypertensive rats. Eur J Pharmacol 1981; 70:467-478.
11. Berecek KH, Kirk KA, Nagahama S, Oparil S: Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. Am J Physiol 1987; 252:H796-H806.
12. Antonaccio MJ, Kerwin L: Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats. Eur J Pharmacol 1980; 68:209-212.
13. Atkinson J, Sonnay M, Sautel M, Fouda A-K: Chronic treatment of the spontaneously hypertensive rat with captopril attenuates response to noradrenaline in vivo but not in vitro. Hypertension 1987;3(suppl II):II211-II215.
14. Okuno I, Kondo K, Konishi K, et al: SQ 14,225 attenuates the vascular response to norepinephrine in the rat mesenteric arteries. Life Sci 1979;25:1343-1350.
15. Boura ALA, Rechtman MP, Walters WAW: Attenuation by captopril of pressor responses to sympathetic stimuli: effects of procedures reducing activity of the renin-angiotensin system. J Auton Pharmacol 1983;3: 203-211.
16. Dominiak P, Elfrath A, Turck D: Effect of chronic treatment with ramipril, a new ACE blocking agent, on presynaptic sympathetic nervous system of SHR. Clin Exp Hypertens 1987;9:369-373.
17. Dominiak P, Elfrath A, Turck D: Biosynthesis of catecholamines and sympathetic outflow in spontaneously hypertensive rats (SHR) after chronic treatment with CE blocking agents. J Cardiovasc Pharmacol 1987;10: S122-S124.
18. Tsuda K, Tsuda S, Ura M, et al: Inhibitory actions of captopril on norepinephrine release from adrenergic nerve endings in spontaneously hypertensive rats. Jpn Heart J 1988;29:475-483.
19. Yasuda G, Shionoiri H, Kubo T, Misu Y: Presynaptic angiotensin II receptors and captopril-induced adrenergic transmission failure probably not via converting enzyme inhibition in guinea-pig pulmonary arteries. J Hypertens 1987;5(suppl 2):S39-S45.
20. Kuo Y-JJ, Keeton TK: Captopril increases norepinephrine spillover rate in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 1991;258:223-231.
21. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF: Non-peptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991;12:55-62.
22. Wong PC, Price WA, Chiu AT, et al: Nonpeptide angiotensin II receptor antagonist: studies with EXP9270 and DuP 753. Hypertension 1990;15:823-834.
23. Wong PC, Hart SD, Zaspel AM, et al: Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther 1990;255:584-592.
24. Wong PC, Price WA, Chiu AT, et al: Hypotensive action of DuP 753, an angiotensin II receptor antagonist in spontaneously hypertensive rats: nonpeptide angiotensin II receptor antagonists: X. Hypertension 1990;15: 459-468.
25. Mendelsohn FAO: Localisation and properties of angiotensin receptors. J Hypertens 1985;3:307-316.
26. Brasch H, Sieroslawski L, Dominiak P: Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 1993; 22:699-704.
27. Hugues J, Roth RH: Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br J Pharmacol 1971;41:239-255.
28. Zimmerman BG, Sybertz EJ, Wong PC: Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984;2:581-587.
29. Soltis EE, Jewell AL, Dwoskin LP, Cassis LA: Acute and chronic effects of losartan (DuP 753) on blood pressure and vascular reactivity in normotensive rats. Clin Exp Hypertens [A] 1993;15(1):171-184.
30. Bunkenburg B, Schnell C, Baum H-P, et al: Prolonged angiotensin II antagonism in spontaneously hypertensive rats: hemodynamic and biochemical consequences. Hypertension 1991;18:278-288.
31. Ohtawa M, Takayama F, Saitoh K, et al: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-297.
32. Oddie CJ, Dilley RJ, Kanellakis P, Bobik A: Chronic angiotensin II type 1 receptor antagonism in genetic hypertension: effects on vascular structure and reactivity. J Hypertens 1993;11:717-724.
33. Johnston H, Majewski H, Musgrave IF: Involvement of cyclic nucleotides in prejunctional modulation of noradrenaline release in mouse atria. Br J Pharmacol 1987; 91:713-720.
34. Starke K, Hedler L. Majewski H: Formation of deaminated catechols from noradrenaline in guinea pig atria and rabbit hearts, in Fleming WW, Graefe K-H, Langer SZ, Weiner N (eds): Neuronal and Extraneuronal Events in Autonomic Pharmacology. New York, Raven Press, 1984, pp 13-21.
35. Suzuki Y, Matsumura Y, Egi Y, Morimoto S: Effects of losartan, a nonpeptide angiotensin II receptor antagonist on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs. J Pharmacol Exp Ther 1992;263:956-963.
36. Wong PC, Bernard R, Timmermans PBMWM: Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension 1992;19:663-667.
37. de Champlain J, Cousineau D, Van Amerigen MR, et al: The role of the sympathetic system in experimental and human hypertension. J Postgrad Med J 1977;53(suppl 3):15-30.
38. de Champlain J, Eid H, Drolet G, et al: Peripheral neurogenic mechanisms in deoxycorticosterone acetate-salt hypertension in the rat. Can J Physiol Pharmacol 1989; 67:1140-1145.
39. Grobecker H, Roizen MF, Weise V, et al: Sympathoadrenal medullary activity in young, spontaneously hypertensive rats. Nature 1975;258:267.
40. Story DF, Ziogas J: Interaction of angiotensin with nor-adrenergic neuroeffector transmission. Trends Pharmacol Sci 1987;8:269-271.
41. Kawasaki H, Cline WH Jr, Su C: Enhanced angiotensin-mediated facilitation of adrenergic neurotransmission in spontaneously hypertensive rats. J Pharmacol Exp Ther 1982;221:112-116.
42. Llona I, Vavrek R, Stewart J, Huidobro-Toro PJ: Identification of pre- and postsynaptic bradykinin receptor sites in the vas deferens: evidence for different structural prerequisites. J Pharmacol Exp Ther 1987;241:608-614.
43. Dominiak P, Simon M, Blöchl A, Brenner P: Changes in peripheral sympathetic outflow of pithed spontaneously hypertensive rats after bradykinin and desArg-bradykinin infusions: influence of converting-enzyme inhibition. J Cardiovasc Pharmacol 1992;20(suppl 9):S35-S38.
44. Yamaguchi N, Nadeau R, de Champlain J: Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. Circ Res 1977;41:108-117.
45. Starke K, Göthert M, Kilbinger H: Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 1989;69:864-989.